4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-21-012128
Chief R&D Officer sold 24,141 shares at $22.37 ($540,034)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2021-02-16 | Sale | −24,141 | $22.37 | $540,034 | 266,176 | D: show line 1 in the form |
| Open-market sales · 24,141 sh · avg $22.37 · $540,034 | |||||||
Loading xslF345X03/doc4.xml…